Mildronāts (Meldonium Dihydrate)

Meldonium inhibits γ‑butyrobetaine dioxygenase, raising intracellular carnitine levels. Higher carnitine enhances the transport of fatty acids into mitochondria, promoting β‑oxidation and more efficient ATP generation. The resulting shift in cardiac substrate use improves oxygen efficiency and provides protective effects during ischemic episodes.

The dosage of Mildronāts is determined by the prescribing clinician based on the individual’s medical condition, severity, and response to therapy. Healthcare professionals tailor the dose to achieve optimal therapeutic benefit while minimizing potential adverse effects.

Safety data for Meldonium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Mildronāts, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meldonium differs from traditional anti‑ischemic agents such as nitrates or calcium‑channel blockers by targeting cellular energy metabolism rather than vasodilation. It increases carnitine‑mediated fatty‑acid oxidation, offering a complementary mechanism that can be used alongside other therapies when appropriate.

Mildronāts should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Mildronāts is administered orally, typically in tablet or capsule form, as directed by a healthcare professional. The medication should be taken with or without food according to the prescriber’s instructions, and the full prescribed course should be completed.

Serious risks, though rare, include severe hypotension, arrhythmias, significant liver enzyme elevations, allergic reactions such as angioedema, and hematologic abnormalities like leukopenia. Patients should be monitored regularly for any signs of these conditions, and therapy should be discontinued if they occur.

Mildronāts is contraindicated in individuals with known hypersensitivity to Meldonium or any of its excipients. Caution is also advised for patients with severe hepatic or renal impairment, uncontrolled hypertension, or those taking medications that may interact significantly, such as MAO inhibitors.